in November 2025<\/a> that they would be partnering.<\/p>\nKyoto University\u2019s Role<\/p>\n
As a research institution, Kyoto is known for groundbreaking innovations in medicine and science. BostonGene, meanwhile, has developed what is the leading AI model for tumor and immune biology.<\/p>\n
Together, their research collaboration expects to support future clinical trial decisions, biomarker-driven patient selection strategies, and broader development efforts.<\/p>\n
In particular, BostonGene and Kyoto University hope to generate insights relative to combination immunotherapy approaches. Regarding the clinical trial, BostonGene\u2019s multimodal AI analytics platform will integrate the study\u2019s genomic, transcriptomic, immune, and clinical data.<\/p>\n
This, ideally, results in identification of molecular signatures and immune-response patterns associated with therapeutic response and resistance.<\/p>\n
\u201cBy combining PDT with ICIs, our goal is to enhance anti-tumor responses where current treatment options remain limited,\u201d Moto said. \u201c[These] profiling capabilities allow us to better characterize the tumor microenvironment and identify biological features associated with durable clinical benefit. Ultimately, this work will help us support more precise and personalized therapeutic strategies for patients with advanced cancers.\u201d<\/p>\n
BostonGene President Weighs In<\/p>\n
Yukimasa Shiotsu, PhD, President of BostonGene Japan, offered further thoughts on the partnership.<\/p>\n
\u201cIntegrating advanced AI-driven multiomics analysis into clinical development is essential for accelerating and de-risking next-generation oncology therapeutics,\u201d Shiotsu said. \u201cThis partnership allows us to better understand the biological mechanisms underlying response to ICI and PDT combination therapy.\u201d<\/p>\n
Dr. Moto\u2019s study, an investigator-initiated trial, has financial support from Meiji Seika Pharma<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Editor\u2019s Take: Collaborations between pharma companies and academic institutions can support future clinical trial decisions and broader development…\n","protected":false},"author":2,"featured_media":778213,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-778212","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/778212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=778212"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/778212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/778213"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=778212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=778212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=778212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}